Program
pumitamig
Also written as “Pumitamig”, “PM8002” and “BNT327”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Small Cell Lung Carcinoma · Breast Neoplasms · Carcinoma, Hepatocellular · Colorectal Neoplasms, led by 4 companies.
Drug pagePumitamig: every studyAll 36 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BioNTechits history only | 2321 open or running | phase 3since May 14, 2024 | Feb 15, 2023 | Jan 1, 2027phase 2 · NCT05879055 |
| Bristol-Myers Squibbits history only | 99 open or running | phase 3since Oct 23, 2025 | Sep 26, 2024 | Mar 15, 2028phase 2 · NCT07871214 |
| Boehringer Ingelheimits history only | 11 open or running | phase 2since Sep 22, 2026 | Sep 22, 2026 | Apr 17, 2030phase 2 · NCT07843940 |
| DualityBio | 11 open or running | phase 2since Apr 9, 2025 | Apr 9, 2025 | Jun 30, 2030phase 2 · NCT06953089 |
- Named in Bristol-Myers Squibb’s own pipeline as
pumitamig
, phase 3, as of Oct 29, 2026 (source).
Also a collaborator on its studies: MediLink Therapeutics (Suzhou), BioNTech (Shanghai) Pharmaceuticals and Genmab.
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- Co-developmentBristol Myers Squibb develops it with BioNTech, worldwide, profits and losses shared equally.Announced Jun 2, 2025 · Source: BioNTech, Jun 2, 2025
How Boehringer Ingelheim and DualityBio relate to it is not in the registry or these sources.
History and studies of DualityBio only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Feb 13, 2025Named pumitamigINNProposed as its International Nonproprietary Name in WHO's List 132 · before, PM8002, BNT327
- Apr 9, 2025First study: phase 2 study in Squamous Cell Carcinoma of Head and NeckFirst studyNCT06953089 · 750 planned · United States, Australia, China and more
- Jun 2, 2025Bristol Myers Squibb develops it with BioNTechCo-developmentWorldwide, profits and losses shared equally · announced · BioNTech
Ahead
- Jun 30, 2030Primary completion: phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT06953089
TargetBeta
“A bispecific antibody targeting both the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and vascular endothelial growth factor A (VEGF-A), with potential immune checkpoint inhibitory, anti-angiogenic and antineoplastic activities. Upon adm…”NCIt, read by Claude
“A bispecific antibody targeting both the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and vascular endothelial growth factor A (VEGF-A), ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| HLX37 | Fosun Pharma | phase 3 | 2 |
Studies
The one study DualityBio leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06953089Squamous Cell Carcinoma of Head and Neck · United States, Australia, China and more | 2 | Recruiting | Jun 30, 2030 | 750 |
How it is read
Names in the registry
- “Pumitamig”, 18 entries
- “PM8002”, 11 entries
- “BNT327”, 3 entries
- “BNT327 Dose Level 1 (DL1)”, 2 entries
- “BNT327 Dose Level 2 (DL2)”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 7 studies
- Small Cell Lung Carcinoma, 4 studies
- Breast Neoplasms, 2 studies
- Carcinoma, Hepatocellular, 2 studies
- Colorectal Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.